6533b7dcfe1ef96bd127210b

RESEARCH PRODUCT

Complications in Immunosuppressive Therapy of Liver Transplant Recipients

Fabio TuzzolinoFabrizio Di FrancescoMarco SpadaBruno GridelliDavide CintorinoGiovanni VizziniSalvatore GruttadauriaDuilio Pagano

subject

AdultGraft RejectionMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicatecomplicationLiver transplantationGastroenterologyTacrolimusYoung AdultLiver diseasePostoperative ComplicationsAdrenal Cortex HormonesInternal medicinemedicineHumansAgedRetrospective Studiesimmunosuppressionbusiness.industryIncidenceLiver DiseasesIncidence (epidemiology)ImmunosuppressionMiddle Agedmedicine.diseaseTacrolimusLiver TransplantationSurgerySurvival RateRegimenCorticosteroidDrug Therapy CombinationFemaleSurgeryrejectionComplicationbusinessImmunosuppressive Agents

description

BACKGROUND: In liver transplantation (LT), modern immunosuppressive protocol is focused on early corticosteroid (CS) weaning. The aim of the study was to investigate all early transplant-related complications using Clavien grading system, in order to identify a significant relation in two homogenous groups of consecutive liver transplanted patients, only different for steroid avoidance in immunosuppressive regimen. MATERIALS AND METHODS: One group was treated with a tacrolimus-based CS-free immunosuppressive protocol, the other one underwent tacrolimus plus low dose CS therapy. The preoperative continuous variables analyzed were age, gender, model for end-stage liver disease (MELD) score, and the pre-allocation score for predicting survival following liver transplantation (P-SOFT). RESULTS: There were 39 patients in Group A (CS free) (37.9%), and 64 patients in Group B (CS on board) (62.1%). No statistically significant differences between the two groups were detected regarding the incidence and Clavien grade of complications (P = 0.116). No significant relation was revealed between Clavien rate of complications and tacrolimus-based CS-free immunosuppressive protocol, comparing the two subgroup of patient with P-SOFT score < 6 and ≥ 6 (P = 0.193). This association was noted comparing the two subgroups on tacrolimus plus low dose CS regimen (P = 0.013). CONCLUSION: In this series, the use of CS in sick patient is associated with higher morbidity identified by the Clavien classification.

https://doi.org/10.1016/j.jss.2010.09.035